Measured: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trymeasured.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Measured” on the pictured label, suggesting Measured is the compounder of those drugs when in fact it is not.”

2. 2

   ““Measured offers compounded GLP-1 treatments made with the same active ingredients found in Wegovy®, Ozempic®, Zepbound®, and Mounjaro®.” “Same active ingredient in Ozempic and Wegovy” “Same active ingredient in Mounjaro and Zepbound””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

trymeasured.com returned a live storefront when we checked in August 2026, offering personalised GLP-1 plans with nutrition support and listing branded options including the Wegovy pill alongside its compounded programme.

The sentence to notice is FDA's own, and it moved. In 2025 the agency's complaint was that same-ingredient copy implied the compounded product was the same as the approved one. Here it says the copy implies the product has been "FDA-approved or otherwise evaluated for safety and effectiveness" — a wider objection, because a reader does not have to conclude the products are identical to come away thinking somebody checked this one. That is a useful lens for a price page: the question is not only whether a site claims equivalence, but whether anything on it leaves you assuming a regulator has looked. Separately, and more concretely, FDA's finding that the vial carries the seller's name rather than the compounder's means the brand on the box is not a guide to who made what you are paying for.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Measured failed to respond.